Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2021

01-09-2021 | Metastasis | Research Article

Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases

Authors: C. Fabregat-Franco, A. Stradella, V. Navarro, J. Linares, M. Galdeano, S. Recalde, R. Velasco, M. Simo, A. Fernadez, A. C. Venthecourt, C. Falo, S. Vazquez, M. Bergamino, R. Villanueva, S. Pernas, M. J. Gil-Gil

Published in: Clinical and Translational Oncology | Issue 9/2021

Login to get access

Abstract

Purpose

Brain metastases (BM) occur in 15–35% of patients with metastatic breast cancer, conferring poor prognosis and impairing quality of life. Clinical scores have been developed to classify patients according to their prognosis. We aimed to check the utility of the Breast Graded Prognostic Assessment (B-GPA) and its modified version (mB-GPA) and compare them in routine clinical practice.

Methods

This is an ambispective study including all patients with breast cancer BM treated in a single cancer comprehensive center. We analyzed the overall survival (OS) from BM diagnosis until death. The Kaplan–Meier method and Cox proportional hazard regression model were used in the analyses. ROC curves were performed to compare both scores.

Results

We included 169 patients; median age was 50 years. HER2-positive and triple negative patients were 33.7% and 20.7%, respectively. At the last follow-up, 90% of the patients had died. Median OS was 12 months (95% confidence interval 8.0–16.0 months). OS was worse in patients with > 3 BM and in patients with triple negative subtype.

Conclusions

In our series, we confirm that B-GPA and mB-GPA scores correlated with prognosis. ROC curves showed that B-GPA and mB-GPA have similar prognostic capabilities, slightly in favor of mB-GPA.
Appendix
Available only for authorised users
Literature
1.
Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer. 1981;48:384–94.PubMedCrossRef
2.
Fokstuen T, Wilking N, Rutqvist LE, et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat. 2000;62:211–6.PubMedCrossRef
3.
Griguolo G, Jacot W, Kantelhardt E, et al. External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: a multicentric European experience. Breast. 2018;37:36–41.PubMedCrossRef
4.
Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419–25.PubMedCrossRef
5.
Subbiah IM, Lei X, Weinberg JS, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol. 2015;33:2239–45.PubMedPubMedCentralCrossRef
6.
7.
Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638–45.PubMedCrossRef
8.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.PubMedCrossRef
9.
10.
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2—positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:3744–52.PubMedPubMedCentralCrossRef
11.
Kast K, Schoffer O, Link T, et al. Trastuzumab and survival of patients with metastatic breast cancer. Arch Gynecol Obstet. 2017;296:303–12.PubMedCrossRef
12.
Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;19(11):1758835919833519.
13.
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2019;382(7):597–609.PubMedCrossRef
14.
15.
Moja L, Brambilla C, Compagnoni A, Pistotti V. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2006;2012(4):C006243.
16.
Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388:2004–14.PubMedPubMedCentralCrossRef
17.
Trovo M, Furlan C, Polesel J, et al. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol. 2018;126:177–80.PubMedCrossRef
18.
Muacevic A, Kreth FW, Tonn JC, Wowra B. Stereotactic radiosurgery for multiple brain metastases from breast carcinoma: feasibility and outcome of a local treatment concept. Cancer. 2004;100:1705–11.PubMedCrossRef
19.
20.
Yomo S, Hayashi M. The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brain radiotherapy for brain metastases. J Neurooncol. 2013;113:459–65.PubMedCrossRef
21.
Soon YY, Tham IWK, Lim KH, et al. Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev. 2014;2014(3):CD09454.
22.
Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21:942–8.PubMedCrossRef
23.
Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70:510–4.PubMedCrossRef
24.
Griguolo G, Dieci MV, Giarratano T, et al. Beyond breast specific—Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. J Neurooncol. 2017;131:369–76.PubMedCrossRef
25.
Sperduto PW, Mesko S, Li J, et al. Beyond an updated graded Prognostic Assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today. Int J Radiat Oncol Biol Phys. 2020;107(2):334–43.PubMedPubMedCentralCrossRef
26.
Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2012;82:2111–7.PubMedCrossRef
27.
Laakmann E, Riecke K, Goy Y, et al. Comparison of nine prognostic scores in patients with brain metastases of breast cancer receiving radiotherapy of the brain. J Cancer Res Clin Oncol. 2016;142:325–32.PubMedCrossRef
28.
Tai CH, Wu CC, Hwang ME, et al. Single institution validation of a modified graded prognostic assessment of patients with breast cancer brain metastases. CNS Oncol. 2018;7:25–34.PubMedPubMedCentralCrossRef
29.
Zhuang Q, Wong RX, Lian WX, et al. Validation of modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: extra-cranial disease progression is an independent risk factor. Ann Palliat Med. 2019;8:390–400.PubMedCrossRef
30.
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36.CrossRefPubMed
31.
Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–46.CrossRefPubMed
32.
Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):123.PubMedPubMedCentralCrossRef
33.
Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–36.PubMedCrossRef
34.
35.
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–205.PubMedPubMedCentralCrossRef
36.
Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24:S26–35.PubMedCrossRef
37.
Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28.CrossRef
38.
Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis. Eur J Cancer. 2017;84:141–8.PubMedCrossRef
39.
Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64–71.PubMedCrossRef
40.
Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–9.PubMedCrossRefPubMedCentral
41.
Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) †. Immune-related Pathol Response Criteria. 2018;29:1634–57.
Metadata
Title
Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases
Authors
C. Fabregat-Franco
A. Stradella
V. Navarro
J. Linares
M. Galdeano
S. Recalde
R. Velasco
M. Simo
A. Fernadez
A. C. Venthecourt
C. Falo
S. Vazquez
M. Bergamino
R. Villanueva
S. Pernas
M. J. Gil-Gil
Publication date
01-09-2021
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2021
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-021-02577-x

Other articles of this Issue 9/2021

Clinical and Translational Oncology 9/2021 Go to the issue

Research Article

Propofol inhibited gastric cancer proliferation via the hsa-miR-328-3p/STAT3 pathway

Research Article

A novel tumor suppressor CECR2 down regulation links glutamine metabolism contributes tumor growth in laryngeal squamous cell carcinoma

Research Article

Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis

Research Article

Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)

Correspondence

Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia

Research Article

Medical ozone induces proliferation and migration inhibition through ROS accumulation and PI3K/AKT/NF-κB suppression in human liver cancer cells in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits